Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
